David Steensma: Our proteomics analysis of the large CANTOS CV trial is now online Blood Advances

David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter.

“Our proteomics analysis of the large CANTOS CV trial is now online Blood Advances led by Janghee Woo (now Winship Cancer Institute of Emory). Clonal hematopoiesis was associated with incident anemia and markers of inflammation which were attenuated by IL-1b inhibitor therapy.”

Source: David Steensma/X